Human stem cell cardiomyocyte assays and screening platforms for predicting cardiac safety risk
We will leverage partner expertise in cardiac safety testing (XTN), stem cell cardiomyocytes (LDN) and screening platforms (NAN) to develop translational safety assays to predict human cardiac risk. We will deliver optimised human stem cell cardiomyocytes and phenotypic assays using the latest generation of screening platforms to meet future market and regulatory requirements for in vitro cardiac safety data on drug development candidates that reliably predicts their clinical cardiac risk.
2 235 660.00€
In vitro Testing, Trials
Other Biotechnology / Molecular technology